Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465606 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02465606 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 55 participants.
The verdict
NCT02465606, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.
Interventions
- DRUG Lebrikizumab
- DRUG Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-07-30 |
| Est. Completion | 2016-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465606
The ClinicalTrials.gov registry entry for NCT02465606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lebrikizumab is the first listed.
NCT02465606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465606 about?
NCT02465606 is a clinical study titled "A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis". The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.
What is the current status of trial NCT02465606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2015-07-30. Estimated completion is 2016-05-30.
What interventions are being tested in trial NCT02465606?
The interventions under investigation include: Lebrikizumab (DRUG), Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%) (DRUG).
Who is sponsoring clinical trial NCT02465606?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.